Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in PCa.

[pjoshea13]

New meta-analysis below.

See also my post of 14 days ago:

"More on the platelets-to-lymphocyte ratio (PLR)."

"A total of 7,228 patients from 18 studies were included in the meta-analysis. Overall, elevated pretreatment NLR was associated with poor overall survival (OS, HR 1.58, ...), progression-free survival (PFS, HR 1.95, ...) and biochemical recurrence-free survival (BRFS, HR 1.37, ...). And high pretreatment PLR was correlated with more inferior PFS (HR 1.62, ...), OS (HR 1.70, ...) and cancer-specific survival (CSS, HR 2.02, ...)."

See my various posts on the importance of controlling subclinical inflammation.

-Patrick

ncbi.nlm.nih.gov/pubmed/304...

Int J Surg. 2018 Nov 20. pii: S1743-9191(18)31714-X. doi: 10.1016/j.ijsu.2018.11.020. [Epub ahead of print]

Prognostic role of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in prostate cancer: a meta-analysis of results from multivariate analysis.

Guo J1, Fang J2, Huang X2, Liu Y2, Yuan Y2, Zhang X2, Zou C3, Xiao K4, Wang J5.

Author information

1

Department of Urology/Shenzhen Urology Minimally Invasive Engineering Center, The Second Clinical Medical College of Jinan University/Shenzhen People's Hospital, Shenzhen, Guangdong Province, China; The Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, The Shenzhen Cell Therapy Public Service Platform, Shenzhen, Guangdong Province, China.

2

Department of Urology/Shenzhen Urology Minimally Invasive Engineering Center, The Second Clinical Medical College of Jinan University/Shenzhen People's Hospital, Shenzhen, Guangdong Province, China.

3

Clinical Medical Research Center, Shenzhen People's Hospital, Shenzhen, Guangdong Province, China.

4

Department of Urology/Shenzhen Urology Minimally Invasive Engineering Center, The Second Clinical Medical College of Jinan University/Shenzhen People's Hospital, Shenzhen, Guangdong Province, China. Electronic address: [e-mail].

5

Department of Urology/Shenzhen Urology Minimally Invasive Engineering Center, The Second Clinical Medical College of Jinan University/Shenzhen People's Hospital, Shenzhen, Guangdong Province, China; The Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, The Shenzhen Cell Therapy Public Service Platform, Shenzhen, Guangdong Province, China. Electronic address: [e-mail].

Abstract

BACKGROUND:

The prognostic role of neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in patients with prostate cancer (PCa) remains inconsistent. Here we quantify the prognostic impact of these biomarkers and assess their consistency in PCa.

MATERIALS AND METHODS:

We systematically searched PubMed, Web of Science, and Embase for eligible studies embracing multivariate results. The Newcastle-Ottawa Scale were used to assess the study quality. Pooled hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated.

RESULTS:

A total of 7,228 patients from 18 studies were included in the meta-analysis. Overall, elevated pretreatment NLR was associated with poor overall survival (OS, HR 1.58, 95% CI 1.41-1.78, P < 0.001), progression-free survival (PFS, HR 1.95, 95% CI 1.53-2.49, P < 0.001) and biochemical recurrence-free survival (BRFS, HR 1.37, 95% CI 1.07-1.75, P = 0.011). And high pretreatment PLR was correlated with more inferior PFS (HR 1.62, 95% CI 1.20-2.19, P = 0.002), OS (HR 1.70, 95% CI 1.34-2.15, P < 0.001) and cancer-specific survival (CSS, HR 2.02, 95% CI 1.24-3.29, P = 0.005). Moreover, the subgroup analyses did not alter the direction of results for OS and PFS.

CONCLUSION:

Based on these findings, elevated NLR and PLR was associated with poor oncologic outcomes, and they can serve as prognostic factors in PCa patients.

Copyright © 2018. Published by Elsevier Ltd.

KEYWORDS:

inflammation; meta-analysis; neutrophil to lymphocyte ratio; platelet to lymphocyte ratio; prognosis; prostate cancer

PMID: 30468905 DOI: 10.1016/j.ijsu.2018.11.020

[cesanon]

Patrick,

Why do you think this should be?

What do you think is the causitive mechanism?

[pjoshea13 in reply to cesanon]

Inflammation.

[cujoe]

Patrick,

Many thanks for this. (Your studious dogged nature delivers once again.)

In addition to PCa, I also have CLL which impacts lymphocytes, neutrophils,and platelets. I will be taking this (and the info from the studies you posted earlier ) to my CLL & PCa oncologists for comment when I see them both late next month.

Be Well - cujoe

[BigM62]

What was the numbers used for determining if the ratio is “high”?

[pjoshea13 in reply to BigM62]

This is from the recent study I mentioned:

"... NLR {neutrophil-to-lymphocyte ratio} ≥ 3 and PLR {platelets-to-lymphocyte ratio} ≥ 210 were considered as elevated levels (high risk groups)."

healthunlocked.com/advanced....

-Patrick